Evidence map›Paper›PMID 42024433›Full record

ArticleFEMS yeast research2026

A CRISPR/Cas9-based genome-editing platform enabling efficient and precise gene replacement in Lipomyces starkeyi.

Rikako Sato, Kaito Maruyama, Satoshi Ara, Masayuki Shibata, Yosuke Shida, Wataru Ogasawara, Harutake Yamazaki, Hiroaki Takaku

Abstract read
In one paragraph

Article in FEMS yeast research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rikako SatoDepartment of Applied Life Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Akiha-ku, Niigata 956-8603, Japan.
Kaito MaruyamaDepartment of Applied Life Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Akiha-ku, Niigata 956-8603, Japan.
Satoshi AraResearch Institute for Creating the Future, FUJI OIL Co., Ltd, Tsukubamirai-shi, Ibaraki 300-2497, Japan.
Masayuki ShibataResearch Institute for Creating the Future, FUJI OIL Co., Ltd, Tsukubamirai-shi, Ibaraki 300-2497, Japan.
Yosuke ShidaDepartment of Bioengineering, Nagaoka University of Technology, Nagaoka, Niigata 940-2188, Japan.
Wataru OgasawaraDepartment of Bioengineering, Nagaoka University of Technology, Nagaoka, Niigata 940-2188, Japan.
Harutake YamazakiDepartment of Applied Life Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Akiha-ku, Niigata 956-8603, Japan.
Hiroaki TakakuDepartment of Applied Life Sciences, Niigata University of Pharmacy and Medical and Life Sciences, Akiha-ku, Niigata 956-8603, Japan.ORCID 0000-0002-3785-8030

Funding

Japan Science and Technology Agency JPMJPF2211JSPS 25K08907JSPS 25K18164JSPS JPJS00420240017New Energy and Industrial Technology Development Organization
6 · The paper itself

Abstract

Lipomyces starkeyi is a promising oleaginous yeast with industrial potential. However, its genome engineering remains constrained by low gene-targeting efficiency and the requirement for long homologous regions. Herein, we established a CRISPR/Cas9 genome-editing platform for L. starkeyi by expressing codon-optimized Streptococcus pyogenes Cas9 fused to an SV40 nuclear localization signal. Furthermore, in vitro-transcribed single-guide RNAs (sgRNAs) were directly delivered into the host, eliminating the need for endogenous RNA polymerase III-dependent sgRNA expression. CRISPR/Cas9 activity was validated using a codon-optimized Aequorea coerulescens GFP reporter. Cas9-induced frameshift mutations caused GFP disruption, leading to fluorescence loss. Gene replacement at the LsURA3 locus was evaluated using donor constructs with homologous regions ranging from 50-3000 bp. In a Cas9-expressing wild-type background, precise gene replacement was dependent on homology arm length, increasing from 36% with 50-bp arms to 80% with 3000-bp arms. Notably, in a Cas9-expressing Δlslig4 strain with suppressed non-homologous end joining (NHEJ), precise gene replacement was achieved with 100% accuracy using 50-bp homology arms under CRISPR/Cas9-dependent conditions. Together, these results demonstrate that a Pol III-independent CRISPR/Cas9 system combined with NHEJ suppression enables precise genome editing in L. starkeyi, providing a foundation for functional genomics and metabolic engineering.

Indexed as

CRISPR-Cas SystemsLipomycesGene TargetingStreptococcus pyogenesCRISPR/Cas9genome editinghomologous recombinationLipomyces starkeyinonhomologous end joiningoleaginous yeast

Identifiers

PMID42024433
PMCPMC13159722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.